Aptera Motors Corp. filed a Form 8-K on November 10, 2026, disclosing the suspension and termination of its at-the-market offering prospectus and providing preliminary cash figures for the quarter ended September 30, 2026.
PepGen Inc. filed a current report on November 10, 2026, disclosing third quarter 2026 financial results and announcing positive Phase 2 FREEDOM2-DM1 data from its 10mg/kg multiple ascending dose cohort.
PDS Biotechnology Corporation filed a Form 8-K on November 10, 2026, disclosing that NantWorks exercised outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of common stock at an exercise price of $0.22 per share, generating approximately $3.9 million in gross proceeds …
Paul J. Hastings submitted an initial statement of beneficial ownership with the SEC on November 10, 2026, in connection with an event date of November 3, 2026, disclosing his status as a director of Azora Therapeutics, Inc. (DE), listed on NASDAQ:AZR.
Atossa Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $23.718 million for the nine months ended September 30, 2026, with cash and cash equivalents of $20.574 million at quarter end.
Nano-X Imaging Ltd filed a Form 6-K with the SEC on November 9, 2026, disclosing that its Board of Directors approved a strategic realignment and efficiency plan targeting a 25%-30% annualized reduction in operating expenses, alongside a global workforce reduction and four renewed strategic …
Nova Ltd. filed a Form 6-K on November 10, 2026, announcing that Chief Financial Officer Guy Kizner will participate in two investor conferences during November and December 2026.
Director Aida Habtezion filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reporting her initial ownership position in Azora Therapeutics, Inc. as of the event date of November 3, 2026.
Thomas M. Soloway, a newly reported director at Azora Therapeutics, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reflecting an event date of November 3, 2026.
The release gave no reason for the split and no Nasdaq deficiency details, so the motive is not confirmed. As general context, companies often use reverse splits to lift the share price above the USD 1.00 minimum bid that Nasdaq requires, yet the split …